Increased Expression Of SOX2 Predicts A Poor Prognosis And Promotes Malignant Phenotypes In Upper Tract Urothelial Carcinoma

References

• Rouprêt M, Babjuk M, Compérat E, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018;73(1):111–122. doi:10.1016/j.eururo.2017.07.03628867446
   PubMed Web of Science ®Google Scholar
• Rebecca LS, Kimberly DM, Ahmedin JD. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.2138728055103
   PubMed Web of Science ®Google Scholar
• Li -C-C, Chang T-H, Wua W-J, et al. significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol. 2008;54(5):1127–1134. doi:10.1016/j.eururo.2008.01.05418243511
   PubMed Web of Science ®Google Scholar
• Holmäng S, Johansson S. Urothelial carcinoma of the upper urinary tract: comparison between the WHO/ISUP 1998 consensus classification and WHO 1999 classification system. Urology. 2005;66(2):274–278. doi:10.1016/j.urology.2005.03.01116098355
   PubMed Web of Science ®Google Scholar
• Lughezzani G, Cisbarn J. Temporal stage and grade migration in surgically treated patients with upper tract urothelial carcinoma. BJU Int. 2010;105(6):799–804. doi:10.1111/j.1464-410X.2009.08818.x19725824
   PubMed Web of Science ®Google Scholar
• Vitaly M, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2010;115(6):1224–1233. doi:10.1002/cncr.24135
   Web of Science ®Google Scholar
• Favaretto RL, Shariat SF, Chade DC, et al. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol. 2010;58(4):574–580. doi:10.1016/j.eururo.2010.07.00320637540
   PubMed Web of Science ®Google Scholar
• Collignon J, Sockanathan S, Hacker A, et al. A comparison of the properties of Sox-3 with sry and two related genes, Sox-1 and Sox-2. Development. 1996;122(2):509–520. PMID:8625802.8625802
   PubMed Web of Science ®Google Scholar
• Ye X, Wu F, Wu C, et al. β-Catenin, a Sox2 binding partner, regulates the DNA binding and transcriptional activity of Sox2 in breast cancer cells. Cell Signal. 2014;26(3):492–501. doi:10.1016/j.cellsig.2013.11.02324291232
   PubMed Web of Science ®Google Scholar
• Sun C, Sun L, Li Y, Kang X, Zhang S, Liu Y. Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating slug. Med Oncol. 2013;30(2):503. doi:10.1007/s12032-013-0503-123430442
   PubMed Web of Science ®Google Scholar
• Zhu F, Qian W, Zhang H, et al. SOX2 is a marker for stem-like tumor cells in bladder cancer. Stem Cell Rep. 2017;9(2):429–437. doi:10.1016/j.stemcr.2017.07.004
   PubMed Web of Science ®Google Scholar
• Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer. 2013;13(10):727–738. doi:10.1038/nrc359724060864
   PubMed Web of Science ®Google Scholar
• Boumahdi S, Driessens G, Lapouge G, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. 2014;511(7508):246–250. doi:10.1038/nature1330524909994
   PubMed Web of Science ®Google Scholar
• Ho P, Kurtova A, Chan KS. Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat Rev Urol. 2012;9(10):583–594. doi:10.1038/nrurol.2012.14222890301
   PubMed Web of Science ®Google Scholar
• Kitamura H, Torigoe T, Hirohashi Y, et al. Prognostic impact of the expression of ALDH1 and SOX2 in urothelial cancer of the upper urinary tract. Mod Pathol. 2013;26(1):117–124. doi:10.1038/modpathol.2012.13922899292
   PubMed Web of Science ®Google Scholar
• Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2937–2944. doi:10.1681/ASN.200604036816988059
   PubMed Web of Science ®Google Scholar
• Nakatsugawa M, Takahashi A, Hirohashi Y, et al. SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. Lab Invest. 2011;91(12):1796–1804. doi:10.1038/labinvest.2011.14021931300
   PubMed Web of Science ®Google Scholar
• Hüser L, Novak D, Umansky V, Altevogt P, Utikal J. Targeting SOX2 in anticancer therapy. Expert Opin Ther Targets. 2018;22(12):983–991. doi:10.1080/14728222.2018.153835930366514
   PubMed Web of Science ®Google Scholar
• Takeda K, Mizushima T, Yokoyama Y, et al. Sox2 is associated with cancer stem-like properties in colorectal cancer. Sci Rep. 2018;8(1):17639. doi:10.1038/s41598-018-36251-030518951
   PubMedGoogle Scholar
• Lee GJ, Lee H, Woo IS, et al. High expression level of SOX2 is significantly associated with shorter survival in patients with thymic epithelial tumors. Lung Cancer. 2019;132(undefined):9–16. doi:10.1016/j.lungcan.2019.03.01631097100
   PubMedGoogle Scholar
• Muraki Y, Hasegawa T, Takeda D, et al. Induced pluripotent stem cell-related genes correlate with poor prognoses of oral squamous cell carcinoma. Anticancer Res. 2019;39(3):1205–1216. doi:10.21873/anticanres.1323130842151
   PubMed Web of Science ®Google Scholar
• Gu W, Wang B, Wan F, et al. SOX2 and SOX12 are predictive of prognosis in patients with clear cell renal cell carcinoma. Oncol Lett. 2018;15(4):4564–4570. doi:10.3892/ol.2018.782829541226
   PubMed Web of Science ®Google Scholar
• Zhang X, Yu H, Yang Y, et al. SOX2 in gastric carcinoma, but not Hath1, is related to patients’ clinicopathological features and prognosis. J Gastrointest Surg. 2010;14(8):1220–1226. doi:10.1007/s11605-010-1246-320532662
   PubMed Web of Science ®Google Scholar
• Wilbertz T, Wagner P, Petersen K, et al. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol. 2011;24(7):944–953. doi:10.1038/modpathol.2011.4921460799
   PubMed Web of Science ®Google Scholar
• Chou YT, Lee CC, Hsiao SH, et al. The emerging role of SOX2 in cell proliferation and survival and its crosstalk with oncogenic signaling in lung cancer. Stem Cells. 2013;31(12):2607–2619. doi:10.1002/stem.151823940081
   PubMed Web of Science ®Google Scholar
• Herreros-Villanueva M, Zhang JS, Koenig A, et al. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis. 2013;2(undefined):e61. doi:10.1038/oncsis.2013.2323917223
   PubMedGoogle Scholar
• Drakulic D, Vicentic JM, Schwirtlich M, et al. The overexpression of SOX2 affects the migration of human teratocarcinoma cell line NT2/D1. An Acad Bras Cienc. 2015;87(1):389–404. doi:10.1590/0001-376520152014035225761220
   PubMed Web of Science ®Google Scholar
• Liu K, Xie F, Gao A, et al. SOX2 regulates multiple malignant processes of breast cancer development through the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis. Mol Cancer. 2017;16(1):62. doi:10.1186/s12943-017-0632-928288641
   PubMed Web of Science ®Google Scholar
• Garg M. Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer. Cancer Metastasis Rev. 2015;34(4):691–701. doi:10.1007/s10555-015-9589-626328525
   PubMed Web of Science ®Google Scholar
• Patel N, Arya M, Muneer A, et al. Molecular aspects of upper tract urothelial carcinoma. Urol Oncol. 2014;32(1):28.e11–e20. doi:10.1016/j.urolonc.2012.10.002
   Web of Science ®Google Scholar
• Garros-Regulez L, Aldaz P, Arrizabalaga O, et al. mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance. Expert Opin Ther Targets. 2016;20(4):393–405. doi:10.1517/14728222.2016.115100226878385
   PubMed Web of Science ®Google Scholar
• Song WS, Yang YP, Huang CS, et al. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells. J Chin Med Assoc. 2016;79(10):538–545. doi:10.1016/j.jcma.2016.03.01027530866
   PubMed Web of Science ®Google Scholar
• Lee SH, Oh SH, Do SI, et al. SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma. Br J Cancer. 2014;111(11):2122–2130. doi:10.1038/bjc.2014.52825321191
   PubMed Web of Science ®Google Scholar
• Li Y, Chen K, Li L, Li R, Zhang J, Ren W. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway. Tumour Biol. 2015;36(12):9823–9828. doi:10.1007/s13277-015-3561-526159849
   PubMed Web of Science ®Google Scholar
• Hütz K, Mejías-Luque R, Farsakova K, et al. The stem cell factor SOX2 regulates the tumorigenic potential in human gastric cancer cells. Carcinogenesis. 2014;35(4):942–950. doi:10.1093/carcin/bgt41024325912
   PubMed Web of Science ®Google Scholar
• Pietrobono S, Morandi A, Gagliardi S, et al. Down-regulation of SOX2 underlies the inhibitory effects of the triphenylmethane gentian violet on melanoma cell self-renewal and survival. J Invest Dermatol. 2016;136(10):2059–2069. doi:10.1016/j.jid.2016.06.61027373978
   PubMed Web of Science ®Google Scholar
• Xu Y, Dong X, Qi P, et al. Sox2 communicates with tregs through CCL1 to promote the stemness property of breast cancer cells. Stem Cells. 2017;35(12):2351–2365. doi:10.1002/stem.272029044882
   PubMed Web of Science ®Google Scholar
• Lundberg IV, Edin S, Eklöf V, Öberg Å, Palmqvist R, Wikberg M. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer. BMC Cancer. 2016;16(undefined):471. doi:10.1186/s12885-016-2509-527411517
   PubMedGoogle Scholar
• Bareiss PM, Paczulla A, Wang H, et al. SOX2 expression associates with stem cell state in human ovarian carcinoma. Cancer Res. 2013;73(17):5544–5555. doi:10.1158/0008-5472.CAN-12-417723867475
   PubMed Web of Science ®Google Scholar